Cytokinetics (CYTK-Q) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Day Low65.68

Day High67.45

Open:65.89

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Realtime quote and/or trade prices are not sourced from all markets.

2 Incredible Growth Stocks to Buy Right Now

Markets Today: Stocks Slip on Hawkish Fed Comments

February 5, 2024

2 Biotechs That Could Get Bought Out in 2024

January 3, 2024

Want Diversified Upside in Biotechnology? Check out LABU

Cytokinetics Reports Second Quarter 2022 Financial Results

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics to Announce Second Quarter Results on August 4, 2022

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics (CYTK) Received its Third Buy in a Row

Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering

Cytokinetics Announces Proposed Convertible Senior Notes Offering

Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil

Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026

Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions

Cytokinetics to Participate in Upcoming Investor Conferences

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress

Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS

Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference

Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil

Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress

Cytokinetics Reports First Quarter 2022 Financial Results

Cytokinetics to Hold Annual Meeting of Stockholders

Cytokinetics to Announce First Quarter Results on May 4, 2022

Cytokinetics Announces Changes to Board of Directors

Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference

Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session

Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Profile

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.